Tissue factor and tissue factor pathway-inhibitor in chronic hepatitis C patients

Abstract number: P0569

Goubran F., Abou El Ala A., El-Deib A., Basma El Din B.

Suez Cannal University, Egypt

Patients suffering from chronic hepatitis C infection (HCV) are known to suffer from bleeding tendency with a prolongation of prothrombin time (PT). Few data are available about the levels of tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in patients with HCV and chronic liver disease (CLD). This work aim to study the levels of TF and TFPI in HCV patients with CLD and to correlate the levels of the above parameters with the biochemical changes that reflect liver cell damage. The study group were three groups. The first group were 16 CLD patients who were positive for HCV antibodies (HCV⁺ CLD). The second group were 16 CLD patients who were negative for HCV antibodies (HCV^- CLD) and the third group were 20 normal controls. The following laboratory tests were performed for each group: TF assay (ELISA), TFPI (ELISA), PT (standard one stage), Bilharzial antibodies (hem-agglutination), Hbs ag (ELISA) lHbs Ab (ELISA) and biochemical liver functions (albumin, ALT, AST, bilirubin).The results of the present study showed that the levels of TF and TFPI were significantly increased in CLD patients compared to the controls. Among CLD group TF and TFPI were significantly increased in HCV⁺ CLD than in HCV^- CLD patients. A negative correlation was found between both levels of TF and TFPI and serum albumin in CLD patients. From our study we concluded that CLD is associated with an increase in TF and TFPI either associated with HCV infection or not. However, in HCV infection the increase in these parameters was more in its absence which could be attributed to the known increase in cytokines.